Liquid Biopsy in the Clinical Management of Cancers
International Journal of Molecular Sciences · 06.08.2024 · 25 (16) · 8594
DOI: 10.3390/ijms25168594 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.08.2024. Verfasst von Ho-Yin Ho und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Neoplasms, Biomarkers, Tumor, Neoplastic Cells, Circulating, Circulating Tumor DNA. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 206 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: research impact fund, internal dept funding.
Abstract (Originalsprache)
Liquid biopsy, a noninvasive diagnosis that examines circulating tumor components in body fluids, is increasingly used in cancer management. An overview of relevant literature emphasizes the current state of liquid biopsy applications in cancer care. Biomarkers in liquid biopsy, particularly circulating tumor DNA (ctDNA), circulating tumor RNAs (ctRNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other components, offer promising opportunities for early cancer diagnosis, treatment selection, monitoring, and disease assessment. The implementation of liquid biopsy in precision medicine has shown significant potential in various cancer types, including lung cancer, colorectal cancer, breast cancer, and prostate cancer. Advances in genomic and molecular technologies such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR) have expanded the utility of liquid biopsy, enabling the detection of somatic variants and actionable genomic alterations in tumors. Liquid biopsy has also demonstrated utility in predicting treatment responses, monitoring minimal residual disease (MRD), and assessing tumor heterogeneity. Nevertheless, standardizing liquid biopsy techniques, interpreting results, and integrating them into the clinical routine remain as challenges. Despite these challenges, liquid biopsy has significant clinical implications in cancer management, offering a dynamic and noninvasive approach to understanding tumor biology and guiding personalized treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Biology & Chemical Technology, The Hong Kong Polytechnic University, Hong Kong SAR, China.
Förderung
- research impact fund
- internal dept funding
Zitieren
APA
Ho, H. Y., Chung, K. K., Kan, C. M., & Wong, S. C. (2024). Liquid Biopsy in the Clinical Management of Cancers. International Journal of Molecular Sciences, 25(16), 8594. https://doi.org/10.3390/ijms25168594
Vancouver
Ho HY, Chung KK, Kan CM, Wong SC. Liquid Biopsy in the Clinical Management of Cancers. International Journal of Molecular Sciences. 2024;25(16):8594. doi:10.3390/ijms25168594
BibTeX
@article{Ho2024,
author = {Ho, Ho-Yin and Chung, Kei-See Kasey and Kan, Chau-Ming and Wong, Sze-Chuen Cesar},
title = {Liquid Biopsy in the Clinical Management of Cancers},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {16},
pages = {8594},
doi = {10.3390/ijms25168594}
}
EUVIMED